In a groundbreaking advancement in the treatment of opioid use disorder (OUD) during pregnancy, researchers supported by the National Institutes of Health (NIH) have demonstrated that weekly injectable extended-release buprenorphine significantly outperforms the conventional daily sublingual administration in promoting opioid abstinence among pregnant individuals. Published in the prestigious journal JAMA Internal Medicine, this study sheds critical light on improving maternal and neonatal outcomes in the face of the ongoing opioid epidemic.
Opioid use disorder during pregnancy presents a profoundly complex clinical challenge marked by the necessity to balance effective addiction treatment with the safety of both mother and fetus. Traditional sublingual buprenorphine, administered daily beneath the tongue, has been the standard pharmacologic approach due to its efficacy in reducing illicit opioid use. However, sublingual treatment has notable limitations, including risks of medication misuse, adherence challenges, and pharmacokinetic fluctuations that cause daily peaks and troughs in blood levels. These fluctuations may inadequately suppress opioid cravings and withdrawal symptoms, potentially leading to intermittent use of illicit opioids during pregnancy.
The NIH-supported multicenter randomized clinical trial enrolled 140 pregnant participants diagnosed with OUD, who were randomized to receive either weekly subcutaneous extended-release buprenorphine injections or standard daily sublingual buprenorphine, with or without naloxone. The extended-release formulation, administered under the skin, offers a pharmacologically stable delivery system that maintains therapeutic buprenorphine plasma concentrations consistently throughout the week. Postpartum participants who were not breastfeeding were given the option to receive monthly extended-release treatments, thereby extending the study’s relevance beyond pregnancy into the critical postpartum period.
Urine drug screenings served as the objective metric for opioid abstinence throughout gestation and up to 12 months postpartum. Analysis revealed that participants receiving the weekly extended-release injections exhibited significantly higher rates of opioid abstinence during pregnancy when compared to the sublingual cohort. Importantly, these superior abstinence rates persisted into the postpartum period, where extended-release therapy was shown to be non-inferior. This finding addresses a major clinical need, as postpartum relapse in OUD is a considerable risk due to factors such as stress, physiological changes, and the demands of new motherhood.
Safety outcomes also favored the extended-release group. Although non-serious adverse events were comparably frequent between both groups, those events in the extended-release cohort were more frequently attributed to the medication itself during pregnancy. Contrastingly, serious maternal adverse events were significantly less common among those receiving injectable buprenorphine throughout the entire study period. The reduction in severe adverse events underscores the enhanced tolerability and potential safety benefits of the extended-release formulation, which may translate into fewer interruptions or discontinuations of therapy in clinical practice.
A crucial concern in managing OUD during pregnancy is the risk of neonatal opioid withdrawal syndrome (NOWS), a condition characterized by withdrawal symptoms in newborns exposed to opioids in utero. This trial found no statistically significant differences in NOWS outcomes between the injectable and sublingual treatment groups. This equivalency suggests that extended-release buprenorphine does not increase harm to neonates compared to traditional treatment, while simultaneously offering superior maternal opioid abstinence benefits.
Beyond its clinical implications, this trial marks a significant methodological milestone as the first randomized controlled study to evaluate extended-release buprenorphine specifically in pregnant and postpartum populations. Prior evidence had established the efficacy of extended-release formulations in non-pregnant adults, but this direct assessment during pregnancy is critical given the unique physiological, pharmacokinetic, and psychosocial factors in this demographic.
Mechanistically, the pharmacokinetics of extended-release buprenorphine enable a steady-state plasma concentration that mitigates the classic peak-trough fluctuations seen with sublingual dosing. This steady exposure more effectively attenuates opioid withdrawal symptoms and cravings, likely contributing to the enhanced abstinence observed. Furthermore, the weekly injection reduces the burden of daily dosing adherence, lowering the risk of missed doses or medication diversion, and thus potentially decreasing illicit opioid use.
Clinicians treating pregnant patients with OUD often face challenges with maintaining consistent adherence to daily medications. The extended-release injectable formulation presents a promising intervention to address this obstacle by simplifying treatment regimens and providing sustained medication coverage. This can enhance treatment retention and support more stable recovery trajectories during the vulnerable prenatal and postpartum timeframes.
The broader public health implications of these findings are substantial. The opioid overdose crisis remains a dire emergency in the United States and globally, with pregnant populations being particularly vulnerable to adverse outcomes. Improving treatment modalities that not only ensure maternal safety but also reduce fetal and neonatal risks is paramount. By validating extended-release buprenorphine’s safety and superior efficacy, this trial empowers clinicians and policymakers to incorporate this formulation into standard care guidelines for managing OUD in pregnancy.
This study also highlights the importance of ongoing NIH-funded research efforts within the NIH Helping to End Addiction Long-term® (NIH HEAL®) Initiative, which targets innovative strategies to combat substance use disorders. The clinical trial’s design, involving randomized allocation and robust follow-up through 12 months postpartum, exemplifies rigorous research methodologies essential for generating actionable evidence in complex populations.
In conclusion, the adoption of weekly injectable extended-release buprenorphine for pregnant individuals with OUD offers a transformative enhancement over daily sublingual administration. Its ability to achieve higher opioid abstinence rates safely, coupled with a comparable neonatal risk profile, positions this treatment as a vital weapon in the fight against the opioid epidemic affecting mothers and infants alike. Future research will be necessary to optimize dosing strategies, evaluate long-term maternal and child outcomes, and expand access to this therapy across diverse healthcare settings.
Subject of Research: Extended-release versus sublingual buprenorphine treatment efficacy and safety in opioid use disorder during pregnancy and postpartum.
Article Title: Extended-release versus Sublingual Buprenorphine in Pregnancy through 12-months Postpartum
News Publication Date: 16-Mar-2026
Web References:
https://doi.org/10.1001/jamainternmed.2026.0057
https://www.nih.gov/heal
https://www.nida.nih.gov
References:
TJ Winhusen, et al. Extended-release versus Sublingual Buprenorphine in Pregnancy through 12-months Postpartum. JAMA Internal Medicine. DOI: 10.1001/jamainternmed.2026.0057
Keywords: opioid use disorder, pregnancy, extended-release buprenorphine, sublingual buprenorphine, neonatal opioid withdrawal syndrome, clinical trial, pharmacokinetics, addiction treatment, maternal health, postpartum, drug adherence, NIH HEAL Initiative
